CANNASIGNAL™
LIVE DATA
🔍
SIGNAL
U.S. Cannabis Market: $31.9B in retail sales across 36 statesNY +94% YoY — fastest growing market, 610 dispensaries operatingFEDERAL: Schedule III rescheduling in progress — 280E relief expected late 2026MI: First-ever sales decline, $3.17B in 2025 — 24% wholesale tax challenged in courtVA HB 642 signed — adult use retail launches Jan 1 2027, apps open July 2026CA: Excise tax locked at 15% through July 2028 per AB 564OK: Governor pushes to eliminate medical program — bipartisan opposition buildingNJ: Cannabis consumption lounges now open in Atlantic City, Newark, MerchantvilleFL: $2.5B market flat YoY — adult use implementation stalled after Nov 2024 ballotFEDERAL RISK INDEX: 37/100 (LOW) — down from 48, rescheduling momentum growingU.S. Cannabis Market: $31.9B in retail sales across 36 statesNY +94% YoY — fastest growing market, 610 dispensaries operatingFEDERAL: Schedule III rescheduling in progress — 280E relief expected late 2026MI: First-ever sales decline, $3.17B in 2025 — 24% wholesale tax challenged in courtVA HB 642 signed — adult use retail launches Jan 1 2027, apps open July 2026CA: Excise tax locked at 15% through July 2028 per AB 564OK: Governor pushes to eliminate medical program — bipartisan opposition buildingNJ: Cannabis consumption lounges now open in Atlantic City, Newark, MerchantvilleFL: $2.5B market flat YoY — adult use implementation stalled after Nov 2024 ballotFEDERAL RISK INDEX: 37/100 (LOW) — down from 48, rescheduling momentum growing

FEDERAL RISK MONITOR

COMPOSITE REGULATORY EXPOSURE INDEX · LAST UPDATED APR 28, 2026

Composite Risk Index
Simple average of 5 federal risk factor scores (0-100)
LOW
33/ 100
LOW RISKMODERATEHIGH RISK
Risk Factor Summary
All five federal exposure categories
IRS 280E Tax Exposure
38
Rescheduling Uncertainty
42
Banking Access (SAFER Act)
42
DEA Enforcement Risk
20
Interstate Commerce Restrictions
25
FEDERAL RESCHEDULING
MEDICAL CANNABIS → SCHEDULE III
Effective Apr 28, 2026 · First federal rescheduling in 55 years
BIFURCATED
DOJ Final Order (Apr 23) moves state-licensed medical cannabis and FDA-approved marijuana drugs from Schedule I to Schedule III. Recreational/adult-use cannabis remains Schedule I. Synthetic THC and hemp-derived products are unaffected. The order is described by working cannabis attorneys as underdrafted, creating bifurcated outcomes — meaningful relief for a narrow cohort of operators, continued uncertainty for the majority. See implementation ambiguity section below.
DEA Registration Deadline
State-licensed medical operators must apply by Jun 22, 2026 to use the expedited pathway
26
DAYS LEFT
WHAT CHANGED
  • Section 280E lifted for DEA-registered medical operators
  • Expedited DEA registration pathway opens (60-day window)
  • Federal acknowledgement of cannabis medical value
  • Foundation laid for further rescheduling action
  • Path to bankruptcy access opens for compliant operators
STILL PENDING
  • 280E status for state-licensed medical operators NOT yet DEA-registered: ambiguous
  • Adult-use markets (the majority of revenue) entirely unaffected
  • Recreational cannabis remains Schedule I
  • DEA hearing Jun 29 - Jul 15 on broader rescheduling
  • Banking access still constrained (SAFER pending)
  • Interstate commerce still prohibited; dormant commerce clause challenges incoming
  • DEA cost-plus servicing model details still being defined
  • Treasury/IRS guidance on retrospective 280E relief pending
HEMP INDUSTRY ALERT
Federal Hemp Ban Countdown
H.R. 5371 redefines hemp — most intoxicating hemp products banned Nov 12, 2026
CRITICAL
169DAYS UNTIL ENFORCEMENT
WHAT CHANGES
Hemp redefined to include total THC (not just delta-9). Delta-8, THCA, THC beverages, and most edibles effectively banned. Max 0.4mg THC per container.
INDUSTRY IMPACT
$28B+ hemp market at risk. 300,000+ jobs affected. Industry pushing for legislative fix in 2026. States with legal hemp-THC markets face preemption.
RISK FACTOR DETAIL
IRS 280E Tax Exposure
38→ STABLE

Apr 23, 2026 DOJ Final Order lifted 280E for DEA-registered state-licensed medical operators. However, the order is unclear on whether state-licensed medical operators NOT yet DEA-registered also escape 280E. Most cannabis attorneys read the order as ambiguous on this point. Adult-use operators (the majority of industry revenue) remain fully subject to 280E. Bifurcation creates new compliance complexity rather than clean relief.

Rescheduling Uncertainty
42↓ IMPROVING

Medical Schedule III in effect Apr 28, 2026, but the order is described by working cannabis attorneys as underdrafted. DEA registration process, cost-plus servicing fees ($113/kg estimated), and bifurcated tax treatment all remain ambiguous. DEA hearing June 29-July 15, 2026 may clarify broader rescheduling. Direction is positive; specifics are still unsettled.

Banking Access (SAFER Act)
42→ STABLE

SAFER Banking Act reintroduced Jan 2026 but no movement. Bifurcated rescheduling complicates banking decisions: institutions must now distinguish DEA-registered medical operators from non-registered medical operators from adult-use operators. Most banks remain reluctant pending clearer federal framework. Recreational operators see no banking benefit.

DEA Enforcement Risk
20→ STABLE

Federal enforcement remains minimal with 41 states having legalized in some form. Cole Memo rescinded but DOJ has not prioritized state-legal cannabis. Apr 23 order creates new DEA registration pathway for state medical licensees but enforcement posture against non-registered operators is unstated.

Interstate Commerce Restrictions
25→ STABLE

Cannabis cannot cross state lines despite federal medical rescheduling. The dormant commerce clause may be increasingly viable as a litigation theory now that some cannabis is federally legal — courts have historically dismissed such claims because cannabis was illegal under federal law. Bifurcation creates new legal openings without resolving the prohibition.

FEDERAL POLICY TIMELINE
Key Federal Developments
Major policy events affecting the cannabis industry
POSITIVE NEGATIVE NEUTRAL
Jun 29, 2026
DEA administrative hearing begins on broader rescheduling — whether all cannabis (including recreational) moves to Schedule III. Concludes by July 15, 2026.
Apr 28, 2026
Schedule III rescheduling takes effect upon Federal Register publication. New DEA registration pathway opens for state medical licensees (60-day window). Implementation creates bifurcated outcomes; cannabis bar describes order as underdrafted.
Apr 23, 2026
DOJ Final Order: state-licensed medical cannabis rescheduled from Schedule I to Schedule III. Recreational marijuana remains Schedule I. Section 280E lifted for medical operators.
Apr 2026
Hemp industry pushes legislative fix before Nov 2026 ban takes effect
Feb 2026
FDA publishes cannabinoid lists per hemp law mandate — compliance deadline for industry
Jan 2026
SAFER Banking Act reintroduced in 119th Congress
STATE EXPOSURE BY MARKET
Federal Risk by State Program
Click any state to view full regulatory profile
Adult Use Markets
Medical Only Markets
280E TAX EXPOSURE AFFECTS ALL STATE MARKETS · FEDERAL RESCHEDULING WOULD MATERIALLY IMPACT OPERATOR ECONOMICS